(Q36885379)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17637721%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

review article

1 reference

title

Monoclonal T-cell receptors: new reagents for cancer therapy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17637721%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17637721%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

author name string

Hans J Stauss

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17637721%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

Michela Cesco-Gaspere

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17637721%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

Sharyn Thomas

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17637721%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

Daniel P Hart

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17637721%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

Shao-An Xue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17637721%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

Angelika Holler

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17637721%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

Graham Wright

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17637721%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

Mario Perro

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17637721%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

Ann-Margaret Little

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17637721%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

Constantina Pospori

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17637721%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

Judy King

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17637721%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

publication date

17 July 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17637721%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17637721%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

volume

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17637721%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17637721%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

page(s)

1744-1750

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17637721%20AND%20SRC:MED&resulttype=core&format=json

Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report

2 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300216

7 January 2021

Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300216

7 January 2021

Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300216

7 January 2021

Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300216

7 January 2021

Reconstitution of Cellular Immunity against Cytomegalovirus in Recipients of Allogeneic Bone Marrow by Transfer of T-Cell Clones from the Donor

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300216

7 January 2021

Complete regression of posttransplant lymphoproliferative disease using partially HLA-matched Epstein Barr virus-specific cytotoxic T cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300216

7 January 2021

Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300216

7 January 2021

Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300216

7 January 2021

Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300216

7 January 2021

Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300216

7 January 2021

Tumor-specific T-bodies: towards clinical application

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300216

7 January 2021

Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300216

7 January 2021

Tumor-specific T cell activation by recombinant immunoreceptors: CD3 zeta signaling and CD28 costimulation are simultaneously required for efficient IL-2 secretion and can be integrated into one combined CD28/CD3 zeta signaling receptor molecule

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300216

7 January 2021

Single-chain antigen recognition receptors that costimulate potent rejection of established experimental tumors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300216

7 January 2021

Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRζ /CD28 receptor

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300216

7 January 2021

Redirected primary T cells harboring a chimeric receptor require costimulation for their antigen-specific activation.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300216

7 January 2021

T cell retargeting with MHC class I-restricted antibodies: the CD28 costimulatory domain enhances antigen-specific cytotoxicity and cytokine production

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300216

7 January 2021

Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300216

7 January 2021

A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300216

7 January 2021

Genetic modification of T lymphocytes for adoptive immunotherapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300216

7 January 2021

Transfer of specificity for human immunodeficiency virus type 1 into primary human T lymphocytes by introduction of T-cell receptor genes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300216

7 January 2021

Functional reconstitution of class II MHC-restricted T cell immunity mediated by retroviral transfer of the alpha beta TCR complex

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300216

7 January 2021

Immunotherapy through TCR gene transfer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300216

7 January 2021

Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300216

7 January 2021

Redirection of antileukemic reactivity of peripheral T lymphocytes using gene transfer of minor histocompatibility antigen HA-2-specific T-cell receptor complexes expressing a conserved alpha joining region

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300216

7 January 2021

High efficiency TCR gene transfer into primary human lymphocytes affords avid recognition of melanoma tumor antigen glycoprotein 100 and does not alter the recognition of autologous melanoma antigens

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300216

7 January 2021

Peptide fine specificity of anti-glycoprotein 100 CTL is preserved following transfer of engineered TCR alpha beta genes into primary human T lymphocytes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300216

7 January 2021

Reconstitution of CD8+ T cells by retroviral transfer of the TCR alpha beta-chain genes isolated from a clonally expanded P815-infiltrating lymphocyte.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300216

7 January 2021

Potentiation of tumor eradication by adoptive immunotherapy with T-cell receptor gene-transduced T-helper type 1 cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300216

7 January 2021

Reprogramming of virus-specific T cells into leukemia-reactive T cells using T cell receptor gene transfer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300216

7 January 2021

A critical role of T cell antigen receptor-transduced MHC class I-restricted helper T cells in tumor protection

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300216

7 January 2021

Elimination of human leukemia cells in NOD/SCID mice by WT1-TCR gene-transduced human T cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300216

7 January 2021

Cancer regression in patients after transfer of genetically engineered lymphocytes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300216

7 January 2021

CD4 T cells in tumor immunity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300216

7 January 2021

Cooperation of Human Tumor-Reactive CD4+ and CD8+ T Cells after Redirection of Their Specificity by a High-Affinity p53A2.1-Specific TCR

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300216

7 January 2021

Simultaneous generation of CD8+ and CD4+ melanoma-reactive T cells by retroviral-mediated transfer of a single T-cell receptor.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300216

7 January 2021

Generation of tumor-specific, HLA class I-restricted human Th1 and Tc1 cells by cell engineering with tumor peptide-specific T-cell receptor genes.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300216

7 January 2021

Primary human lymphocytes transduced with NY-ESO-1 antigen-specific TCR genes recognize and kill diverse human tumor cell lines

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300216

7 January 2021

Generation of T cell help through a MHC class I-restricted TCR.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300216

7 January 2021

Redirecting human CD4+ T lymphocytes to the MHC class I-restricted melanoma antigen MAGE-A1 by TCR alphabeta gene transfer requires CD8alpha

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300216

7 January 2021

CD8alpha/alpha homodimers fail to function as co-receptor for a CD8-dependent TCR.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300216

7 January 2021

The T cell receptor: critical role of the membrane environment in receptor assembly and function

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300216

7 January 2021

Efficiency of T-cell receptor expression in dual-specific T cells is controlled by the intrinsic qualities of the TCR chains within the TCR-CD3 complex.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300216

7 January 2021

Designer T cells by T cell receptor replacement.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300216

7 January 2021

A retroviral vector system 'STITCH' in combination with an optimized single chain antibody chimeric receptor gene structure allows efficient gene transduction and expression in human T lymphocytes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300216

7 January 2021

Retroviral vectors for high-level transgene expression in T lymphocytes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300216

7 January 2021

Enhanced antitumor activity of murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stability

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300216

7 January 2021

Codon modification of T cell receptors allows enhanced functional expression in transgenic human T cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300216

7 January 2021

Correction of multi-gene deficiency in vivo using a single 'self-cleaving' 2A peptide-based retroviral vector

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300216

7 January 2021

Suppression of T-cell functions by human granulocyte arginase

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300216

7 January 2021

Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300216

7 January 2021

Facilitating matched pairing and expression of TCR chains introduced into human T cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300216

7 January 2021

Transgenic TCR expression: comparison of single chain with full-length receptor constructs for T-cell function.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300216

7 January 2021

Generation of functional antigen-specific T cells in defined genetic backgrounds by retrovirus-mediated expression of TCR cDNAs in hematopoietic precursor cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300216

7 January 2021

Long-term in vivo provision of antigen-specific T cell immunity by programming hematopoietic stem cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300216

7 January 2021

Rapid analysis of T-cell selection in vivo using T cell-receptor retrogenic mice.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300216

7 January 2021

A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300216

7 January 2021

Gene therapy. Second child in French trial is found to have leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300216

7 January 2021

Gene therapy: is IL2RG oncogenic in T-cell development?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300216

7 January 2021

Gene therapy: X-SCID transgene leukaemogenicity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300216

7 January 2021

Gene therapy: therapeutic gene causing lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300216

7 January 2021

Retroviral vector integration deregulates gene expression but has no consequence on the biology and function of transplanted T cells.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300216

7 January 2021

Extrathymic generation of tumor-specific T cells from genetically engineered human hematopoietic stem cells via Notch signaling

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300216

7 January 2021

Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300216

7 January 2021

IL-21 sustains CD28 expression on IL-15-activated human naive CD8+ T cells.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300216

7 January 2021

Human T lymphocytes transduced by lentiviral vectors in the absence of TCR activation maintain an intact immune competence

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300216

7 January 2021